SCHEMBL2482652

SCHEMBL2482652

O=c1[nH]c2c([N+](=O)[O-])cccc2o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.49
PARP1 P09874 1/20 0.49
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 1/20 0.45
MCL1 Q07820 1/20 0.44
OGT O15294 1/20 0.43
TDP1 Q9NUW8 3/20 0.42
APEX1 P27695 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
NOS3 P29474 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3910847 0.81 PSMB8 (0.53) PARP1MAPTMEN1KMT2ANPC1
SCHEMBL6802027 0.80 PARP1 (0.58) PARP1MAPTMEN1KMT2ANPC1
SCHEMBL21048201 0.75 ALDH1A1 (0.46) EPHX2MAPTMEN1KMT2ANPC1
SCHEMBL9954720 0.73 GPR35 (0.40) EPHX2MAPTMEN1KMT2ANPC1
SCHEMBL2149156 0.72 OGT (0.43) PARP1MAPTGAAOGTTDP1
SCHEMBL5540274 0.71 MCL1 (0.49) EPHX2MCL1OGTNOS1GRM5
SCHEMBL2484702 0.71 MCL1 (0.49) EPHX2PARP1MCL1OGTTDP1
SCHEMBL3043379 0.71 MCL1 (0.49) EPHX2MCL1OGTGRM5
SCHEMBL1285749 0.71 EPHX2 (0.50) EPHX2MCL1OGTNOS3NOS1
SCHEMBL5077255 0.71 PSMB8 (0.61) EPHX2MCL1OGTCYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110156712-A It is a kind of to utilize aromatic nitration by-product synthesis benzoxazoles class compound and application 邵玉田 2019-08-23 CN disclosed
US-10233177-B2 TRPV1 vanilloid receptor antagonists with a bicyclic portion SERENTRIX, LLC 2019-03-19 US disclosed
EP-2552888-B1 TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION SERENTRIX LLC (US) 2018-09-26 EP disclosed
US-20170152252-A1 TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion SERENTRIX, LLC 2017-06-01 US disclosed
US-20160289199-A1 TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion SERENTRIX LLC (US) 2016-10-06 US disclosed
US-9216975-B2 TRPV1 vanilloid receptor antagonists with a bicyclic portion Serentrix, LLC. (US) 2015-12-22 US disclosed
US-20130079339-A1 TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION PHARMESTE S.R.L. (IT) 2013-03-28 US disclosed
EP-2552888-A1 \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ Pharmeste S.r.l. (IT) 2013-02-06 EP disclosed
EP-2377850-A1 TRPV1 vanilloid receptor antagonists with a bicyclic portion Pharmeste S.r.l. (IT) 2011-10-19 EP disclosed
EP-2377850-A1 TRPV1 vanilloid receptor antagonists with a bicyclic portion Pharmeste S.r.l. (IT) 2011-10-19 EP disclosed
WO-2011120604-A1 \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ PHARMESTE S.R.L. (IT) 2011-10-06 WO disclosed
US-7816376-B2 Cyclic amides MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
EP-1485363-B1 CYCLIC AMIDES MERCK PATENT GMBH (DE) 2008-10-08 EP disclosed
US-20050124627-A1 Cyclic amides MERCK PATENT GMBH (DE) 2005-06-09 US disclosed
EP-1485363-A1 CYCLIC AMIDES MERCK PATENT GmbH (DE) 2004-12-15 EP disclosed
WO-2003076420-A1 CYCLIC AMIDES MERCK PATENT GMBH (DE) 2003-09-18 WO disclosed
EP-0406993-A2 Substituted benzoxazolinone and benzoxazinone derivatives, process for their preparation and their use as agent with herbicide activity SCHERING AKTIENGESELLSCHAFT (DE) 1991-01-09 EP disclosed
US-4668610-A 2-equivalent cyan dye-forming 5-hydroxy-6-acylamino-benzoxazole-2-one couplers, silver halide photographic elements and processes employing them MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-05-26 US disclosed
EP-0193051-A2 2-Equivalent cyan dye-forming 5-hydroxy-6-acylamino-benzoxazole-2-one couplers, silver halide photographic elements and processes employing them MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152252-A1 TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion TRPV1, TRPV5, TRPV3 EPHX2 964/4885PARP1 2505/4885MAPT 3327/4885
US-20050124627-A1 Cyclic amides NPY1R, GRIK1, GRIK4 EPHX2 917/4885PARP1 2584/4885MAPT 451/4885
US-10233177-B2 TRPV1 vanilloid receptor antagonists with a bicyclic portion TRPV1, TRPV5, TRPV3 EPHX2 964/4885PARP1 2505/4885MAPT 3327/4885
US-20160289199-A1 TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion TRPV1, TRPV5, TRPV3 EPHX2 964/4885PARP1 2505/4885MAPT 3327/4885
US-20130079339-A1 TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION TRPV1, TRPV5, TRPV3 EPHX2 964/4885PARP1 2505/4885MAPT 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.